|
PolyMedix is developing novel,
first in class therapies for serious, life
threatening, acute disorders. Using our
proprietary computational drug design technology, we
have created our two lead product candidates which
have completed Phase 1B clinical trials. PMX-60056
is a synthetic, small-molecule designed as an
anticoagulant reversing agent and PMX-30063 is an
antibiotic that mimics natural host defense proteins.
Phase 2 studies for both of these products are
planned to commence during 2010.
PolyMedix’s approach to developing high-value
therapeutic drugs is with biomimetics - novel
small molecule compounds and polymers which mimic
the activity of proteins. These compounds are
designed with a proprietary computational technology
platform which focuses on a specific field of
biology with many potential product opportunities:
membrane:protein and protein:protein interactions.
PolyMedix is a publicly traded
company (OTC BB:PYMX).
| Upcoming Events |
|
|
September 12 – 15, 2010
ICAAC – Interscience Conference on Antimicrobial
Agents and Chemotherapy
Boston, MA, USA |
|
|
|
September 13, 2010 @
12:30 Eastern Time
Rodman & Renshaw Global Investment Conference
New York, NY, USA |
|
|
|
September 16, 2010
BioPharm America 2010
Boston, MA, USA |
|
|
|
September 22 - 23, 2010
Life Sciences Summit 2010
Long Island, NY, USA |
|
|
|
September 29-30, 2010
10th
Annual Biotech in Europe Investor Forum
Zurich, Switzerland |
|
|
|
October 11 – 13, 2010
33rd World Congress – International Society of
Hematology
Jerusalem, Israel |
|
|
|
November 13 – 17, 2010
American Heart Association – Scientific Session 2010
Chicago, IL, USA |
|
|
|
|
|
|
